China Sky One Medical, with its near-constant barrage of press releases, sometimes seems like an overactive child who always demands attention. On the other hand, the company’s insistent press release schedule is understandable because the company is growing rapidly, its finances are in good order, but investors don’t seem to be paying attention. Today, the company announced that its Heilongjiang Tianlong Pharmaceutical subsidiary has completed its R&D on 26 new drugs and submitted the drugs to the SFDA for approval. More details...

Stock Symbol: (AMEX: CSY)